Identification Of Biomarkers For Early Detection Of Pancreatic Cancer

Study Overview

Identification of Biomarkers for Early Detection of Pancreatic Cancer

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer.

OBJECTIVES: * Identify specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer. * Analyze serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis. OUTLINE: Blood from patients is collected prior to treatment. Plasma proteins are analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS) and/or electrospray mass spectrometry (ESI/MS). PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.

Pancreatic Cancer

GENETIC: protein expression analysis
OTHER: laboratory biomarker analysis
OTHER: mass spectrometry
OTHER: surface-enhanced laser desorption/ionization-time of flight mass spectrometry

CDR0000479140
P30CA022453 (U.S. NIH Grant/Contract)
WSU-C-2737
WSU-013105MP2E

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2009-05-09	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2016-03-07
First Submitted that Met QC Criteria 2009-05-09	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ESTIMATED) 2016-03-09
First Posted (ESTIMATED) 2009-05-12	Results First Posted N/A	Last Verified 2016-03

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Primary Outcome Measures	Measure Description	Time Frame
Identification of specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer		Upon collection when patient agrees to provide a one time venous blood collection
Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis		After separation from the plasma

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Diagnosis of pancreatic cancer

Newly diagnosed disease
Planning to undergo surgery or other treatment for pancreatic cancer at Karmanos Cancer Institute or its affiliates

Not specified

See Disease Characteristics

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

National Cancer Institute (NCI)

Investigators

PRINCIPAL_INVESTIGATOR: Fazlul Sarkar, MD, Barbara Ann Karmanos Cancer Institute

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record